Literature DB >> 22161851

Effect of combined dexamethasone/lenalidomide therapy on NK cell-receptor levels in myeloma patients.

Clive R Carter, Sylvia Feyler, Natuley Smalle, Gina B Scott, Christopher Parrish, Katherine Cullen, Charlotte Kallmeyer, Philip M Wood, Gordon Cook.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22161851     DOI： 10.1182/blood-2011-08-372680

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

1.  A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Authors:  Don M Benson; Adam D Cohen; Sundar Jagannath; Nikhil C Munshi; Gary Spitzer; Craig C Hofmeister; Yvonne A Efebera; Pascale Andre; Robert Zerbib; Michael A Caligiuri
Journal:  Clin Cancer Res       Date:  2015-05-21       Impact factor: 12.531

2.  Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?

Authors:  Andy Hsu; David S Ritchie; Paul Neeson
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

Review 3.  Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.

Authors:  Massimo Giuliani; Bassam Janji; Guy Berchem
Journal:  Oncotarget       Date:  2017-04-04

4.  Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.

Authors:  Johan Lund; Astrid Gruber; Birgitta Lauri; Adil Doganay Duru; Cecilie Blimark; Agneta Swedin; Markus Hansson; Karin Forsberg; Lucia Ahlberg; Conny Carlsson; Anders Waage; Peter Gimsing; Annette Juul Vangsted; Ulf Frølund; Erik Holmberg; Gösta Gahrton; Evren Alici; Mats Hardling; Ulf-Henrik Mellqvist; Hareth Nahi
Journal:  Cancer Med       Date:  2018-04-19       Impact factor: 4.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.